TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02453100

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobility and pelvic floor exercise
Description: Mobility and pelvic floor exercises

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Education
Description: Education on simple ways to manage incontinence

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Education on simple ways to manage incontinence
Study: NCT03163069

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: in-office bleaching with the conventional whitening dentifrice
Description: Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth (2 sessions, with a 1-week interval). During the tooth bleaching procedure and 3 weeks after the procedure, the participants will be instructed to brush their teeth twice with the conventional whitening dentifrice.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: in-office bleaching with the whitening dentifrice containing blue covarine
Description: Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth (2 sessions, with a 1-week interval). During the tooth bleaching procedure and 3 weeks after the procedure, the participants will be instructed to brush their teeth twice with the whitening dentifrice containing blue covarine.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: in-office bleaching with the regular dentifrice
Description: Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth (2 sessions, with a 1-week interval). During the tooth bleaching procedure and 3 weeks after the procedure, the participants will be instructed to brush their teeth twice with the regular dentifrice.
Study: NCT02786186

Intervention type: DRUG
Intervention: Secikinumab

Intervention type: DRUG
Intervention: Secikinumab
Study: NCT00694031

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemodialysis
Description: 3 times per week

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: On-line hemodiafiltration
Description: 3 times per week
Study: NCT04261322

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: x ray exposure
Description: exposure of whole body to x ray

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: x ray exposure
Description: exposure of whole body to x ray

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: x ray exposure
Description: exposure of whole body to x ray

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: x ray exposure
Description: exposure of whole body to x ray
Study: NCT00755937

Intervention type: OTHER
Intervention: Data collection post infusion
Study: NCT02595541

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: milrinone
Description: IV milrinone (0.75 mcg/kg) loading dose over one hour started during re-warming of the patient (before weaning from CPB) and followed by a maintenance dose of 0.75 mcg/kg/minutes till the end of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: milrinone
Description: IV milrinone (0.75 mcg/kg) loading dose over one hour started during re-warming of the patient (before weaning from CPB) and followed by a maintenance dose of 0.75 mcg/kg/minutes till the end of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: IV milrinone (0.75 mcg/kg) loading dose over one hour started during re-warming of the patient (before weaning from CPB) and followed by a maintenance dose of 0.75 mcg/kg/minutes till the end of the study. After baseline measurements, sildenafil (1mg/kg) administered in ICU via a nasogastric tube, to be repeated every 4 hours via a nasogastric tube or orally. Sildnafil is presented in tablet form which was dissolved in water to make a concentration of 1 mg/ml.
Study: NCT03547531

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Natural Tooth Brushing Method
Description: Natural tooth brushing method is the method that is naturally used by the people with horizontal, rotary, or simple up and down motions and any position of the brush without any instruction of particular tooth brushing method.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Circular Tooth Brushing Method
Description: Modified Circular tooth brushing method is a combination of small circular motion of brushing with the position of the brush slightly reach underneath the gingival that are applied for each jaw in all facial surfaces and posterior lingual of tooth arches.
Study: NCT02613416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: monthly subcutaneous injections
Study: NCT04717232

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blended learning approach to mentoring education for dental health care professionals
Description: The participants in the intervention group are dentists´ and dental hygienists´. The mentoring education for dental health care professionals (3 ECTS credits) will be organized by the program leader in Dentistry at the place-blinded. The aim of the mentoring education is to build understanding of how to support a student's professional development (both basic education and specialization) and transfer skills that are relevant to working as an independent expert in oral health care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blended learning approach to mentoring education for dental health care professionals
Description: The participants in the intervention group are dentists´ and dental hygienists´. The mentoring education for dental health care professionals (3 ECTS credits) will be organized by the program leader in Dentistry at the place-blinded. The aim of the mentoring education is to build understanding of how to support a student's professional development (both basic education and specialization) and transfer skills that are relevant to working as an independent expert in oral health care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The interprofessional online mentoring education
Description: The participants in the intervention group are dentists´ and dental hygienists´. The interprofessional online mentoring education (3 ECTS credits) will be organized in collaboration with the Finnish Dental Association in an online environment. The aim of the intervention is to in-crease mentors' competence in guidance processes and interactions, supporting students´ goal-oriented learning and professional evaluation, and providing constructive feedback.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The interprofessional online mentoring education
Description: The participants in the intervention group are dentists´ and dental hygienists´. The interprofessional online mentoring education (3 ECTS credits) will be organized in collaboration with the Finnish Dental Association in an online environment. The aim of the intervention is to in-crease mentors' competence in guidance processes and interactions, supporting students´ goal-oriented learning and professional evaluation, and providing constructive feedback.
Study: NCT02394600

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one tablet daily for four months
Study: NCT02545569

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hearing aid (MD class IIa) - ITE, BTE, RIC
Description: Hearing aid means any wearable instrument or device designed for, offered for the purpose of, or represented as aiding persons with or compensating for, impaired hearing.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hearing aid (MD class IIa) - ITE, BTE, RIC
Description: Hearing aid means any wearable instrument or device designed for, offered for the purpose of, or represented as aiding persons with or compensating for, impaired hearing.
Study: NCT01662492

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A Dose 1
Description: Botulinum toxin type A Dose 1 intramuscular injections into specified muscles.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A Dose 2
Description: Botulinum toxin type A Dose 2 intramuscular injections into specified muscles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Normal Saline)
Description: Placebo (Normal Saline) intramuscular injections into specified muscles.
Study: NCT02174640

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Coffee
Description: Coffee Beverage

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Water
Study: NCT04407182

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Viusid and Asbrip
Description: Patients will be randomized to receive daily doses of 30 ml of Viusid and 10 ml of Asbrip every 8 hours plus standard care. Viusid and Asbrip will be administered orally.~Treatment duration: 21 days.
Study: NCT02853877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly Incentive
Description: The tailored incentives intervention aims to assess the impact of tailored messaging and financial incentives on weight loss among obese employees.
Study: NCT02050386

Intervention type: OTHER
Intervention: Cold pressor stimulation
Description: Immersion of the foot in 0-2 degrees C water for 50 seconds

Intervention type: OTHER
Intervention: Sham Stimulation
Description: Immersion of the foot in room temperature water for 50 seconds
Study: NCT01808417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Near Infrared Imaging
Description: The intervention to be administered is the drug indocyanine green.
Study: NCT00053027

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cladribine
Study: NCT03455647

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ASF promotion plus Girinka
Description: Behavior change communication promoting the consumption of milk produced in the household and other optimal maternal and child nutrition practices. The intervention will be implemented by government of Rwanda Community Health Workers.
Study: NCT01979588

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: What's Going Around tool
Description: Provider has access to the What's Going Around tool

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Provider does not have access to the What's Going Around tool but received information regarding the tool prior to study initiation
Study: NCT04040959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside
Description: Nicotinamide riboside is a naturally occurring vitamin B3 derivative found in yeast, bacteria, and mammalian tissues, and also has been detected in cows' milk.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicotinamide riboside
Description: Nicotinamide riboside is a naturally occurring vitamin B3 derivative found in yeast, bacteria, and mammalian tissues, and also has been detected in cows' milk.
Study: NCT02185235

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation
Description: The Chartered Society of Physiotherapy recommends the following standard for electrical devices.~Frequency: 35 Hertz. Pulse width: 250µs (0.25ms). Current type: bi-phasic rectangular. Intensity: maximum tolerated. Duty-cycle: 5 seconds on/10 seconds off. Very weak muscles: 5 seconds on/15 seconds off.~Treatment time: 5 minutes initially, gradually increasing to 20 minutes.
Study: NCT01745263

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: 2000 IU/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: 2000 IU/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3 fatty acids
Description: Ratio EPA:DHA = 1:2~1 g/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3 fatty acids
Description: Ratio EPA:DHA = 1:2~1 g/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3 fatty acids
Description: Ratio EPA:DHA = 1:2~1 g/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3 fatty acids
Description: Ratio EPA:DHA = 1:2~1 g/d

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Strength Home Exercise

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Strength Home Exercise

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Strength Home Exercise
Study: NCT02185235

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: Biofeedback is a treatment technique in which people are trained to improve their health by using signals from their own bodies

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback
Description: Biofeedback is a treatment technique in which people are trained to improve their health by using signals from their own bodies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Floor Training
Description: First, as you are sitting or lying down, try to contract the muscles you would use to stop urinating To contract the pelvic muscles, squeeze for 3 seconds and then relax for 3 seconds.~Repeat this exercise to 20 minutes each session.
Study: NCT00944008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DepoCyte
Study: NCT02119182

Intervention type: BEHAVIORAL
Intervention: In-Person Outcome Assessment
Description: NIH Flexible Outcome Assessment Battery Framework Measures In-Person at 2 Weeks, 6 Months, and 12 Months, and by Phone at 3 Months.

Intervention type: BEHAVIORAL
Intervention: In-Person Outcome Assessment
Description: NIH Flexible Outcome Assessment Battery Framework Measures In-Person at 2 Weeks, 6 Months, and 12 Months, and by Phone at 3 Months.

Intervention type: BEHAVIORAL
Intervention: Phone Outcome Assessment
Description: NIH Flexible Outcome Assessment Battery Framework Measures by Phone at 2 Weeks, 3 Months, 6 Months, and 12 Months.

Intervention type: PROCEDURE
Intervention: 3T Magnetic Resonance Imaging (MRI)
Description: 3T Research MRI at 2 weeks and 6 months.

Intervention type: PROCEDURE
Intervention: 3T Magnetic Resonance Imaging (MRI)
Description: 3T Research MRI at 2 weeks and 6 months.

Intervention type: PROCEDURE
Intervention: Blood Draw for Plasma, DNA, Serum, RNA
Description: Blood Draw for Plasma, DNA, Serum, RNA at baseline, in hospital (if applicable), 2 weeks, and 6 months (DNA at baseline only).

Intervention type: PROCEDURE
Intervention: Blood Draw for Plasma, DNA, Serum, RNA
Description: Blood Draw for Plasma, DNA, Serum, RNA at baseline, in hospital (if applicable), 2 weeks, and 6 months (DNA at baseline only).
Study: NCT02546037

Intervention type: DEVICE
Intervention: FX100 dialyzer
Description: comparison of dialyzers

Intervention type: DEVICE
Intervention: SOLACEA 21H
Description: comparison of dialyzers
Study: NCT03859570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Pentoxifylline (PTX) is a methylxanthine derivative that is a nonselective inhibitor of cyclic nucleotide phosphodiesterase (PDE). This enzyme, which has at least 5 subtypes, is responsible for inactivation of the important second messengers, Cyclic adenosine monophosphate (AMP) and cyclic guanosine monophosphate (GMP)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo
Study: NCT02669628

Intervention type: PROCEDURE
Intervention: Surgical technique
Description: Laparoscopic surgery

Intervention type: PROCEDURE
Intervention: Alcohol sclerotherapy
Description: US-guided sclerotherapy
Study: NCT02816554

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: JEVAX
Description: JEVAX - VABIOTECH Vietnam Liquid form Subcutaneous injection 0.5ml/dose, 2 doses, 10-12 days interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JECEVAX-1
Description: JECEVAX - VABIOTECH Vietnam Liquid form Composition: 1 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JECEVAX-0.8
Description: JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.8 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JECEVAX-0.5
Description: JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
Study: NCT04106401

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: carbon-monoxide rebreathing
Description: Inhaled carbon monoxide (CO) administrated as a bolus into a rebreathing circuit serves as a marker to tag circulating hemoglobin molecules and to calculate total hemoglobin mass (Hbmass). The change in blood CO concentration from pre- to postadministration (delta carboxyhemoglobin concentration) and the dose of administrated CO allows for Hbmass determination. The other blood compartments (total red blood cell volume, plasma volume and total blood volume) are derived from Hbmass, hematocrit and/or hemoglobin concentration.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: carbon-monoxide rebreathing
Description: Inhaled carbon monoxide (CO) administrated as a bolus into a rebreathing circuit serves as a marker to tag circulating hemoglobin molecules and to calculate total hemoglobin mass (Hbmass). The change in blood CO concentration from pre- to postadministration (delta carboxyhemoglobin concentration) and the dose of administrated CO allows for Hbmass determination. The other blood compartments (total red blood cell volume, plasma volume and total blood volume) are derived from Hbmass, hematocrit and/or hemoglobin concentration.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: venous blood sampling
Description: venous blood sampling at rest to evaluate blood viscosity, erythropoiesis and iron metabolism

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: venous blood sampling
Description: venous blood sampling at rest to evaluate blood viscosity, erythropoiesis and iron metabolism

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical activity monitoring
Description: recording of physical activity by actimetry

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical activity monitoring
Description: recording of physical activity by actimetry

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: apnea-hypopnea index and nocturnal oxygenation
Description: recorded by ambulatory sleep recording device

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: apnea-hypopnea index and nocturnal oxygenation
Description: recorded by ambulatory sleep recording device

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 24-hour blood pressure
Description: recorded by ambulatory device

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 24-hour blood pressure
Description: recorded by ambulatory device
Study: NCT01715415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267, ABT-333
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267, ABT-333
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Capsule (double-blind treatment period), tablet (open-label treatment period)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Capsule (double-blind treatment period), tablet (open-label treatment period)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABT-450/r/ABT-267
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABT-333
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ribavirin
Description: Capsule
Study: NCT01959230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine Tartrate
Description: Ophthalmic solution to be applied as directed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Ophthalmic solution to be applied as directed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Fluorescein
Description: For use as needed during the study for evaluating corneal damage.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Fluorescein
Description: For use as needed during the study for evaluating corneal damage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP
Description: For use as needed during the study for intraocular pressure and dilated ophthalmoscopy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP
Description: For use as needed during the study for intraocular pressure and dilated ophthalmoscopy.
Study: NCT04112615

Intervention type: DEVICE
Intervention: Blood measurement
Description: Single fingerprick to measure haemoglobin and haematocrit measurements using a potential haemoglobin home monitoring system.

Intervention type: DEVICE
Intervention: Blood measurement
Description: Single fingerprick to measure haemoglobin and haematocrit measurements using a potential haemoglobin home monitoring system.
Study: NCT02586688

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active NeuroStar® Transcranial Magnetic Stimulation (TMS)
Description: Compare active NeuroStar® coil with sham NeuroStar® coil.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham NeuroStar® Transcranial Magnetic Stimulation (TMS)
Description: Compare active NeuroStar® coil with sham NeuroStar® coil.

Intervention type: DEVICE
Group type: OTHER
Intervention: Open Label Active NeuroStar® TMS
Description: Open label NeuroStar® coil.

Intervention type: DEVICE
Group type: OTHER
Intervention: Open Label Active NeuroStar® TMS
Description: Open label NeuroStar® coil.
Study: NCT00478634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001, Cetuximab, Irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001, Cetuximab, Irinotecan